Dalbavancin Study Results To Be Presented At IDWeek 2013

CHICAGO, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that data from the company's lead product candidate, dalbavancin, will be presented in five posters during the IDWeek conference in San Francisco from October 2-6, 2013.

The following posters will be presented on Saturday, October 5, 2013:

Title: An Analysis of the Safety Profile of Dalbavancin from the Phase 2/3 Clinical Program

Michael Dunne, MD, Durata Therapeutics, Inc., Branford, CT, Anita Das, PhD, InClin, San Francisco, CA and Sailaja Puttagunta, MD, Durata Therapeutics, Branford, CT

Poster #: 1334

Title: Microbiologic Analyses of Target Pathogens Identified in the Dalbavancin DISCOVER Program

Authors: Michael Dunne, MD, Durata Therapeutics, Inc., Branford, CT, Helen Boucher, MD, FIDSA, Tufts New Engl Med Ctr, Boston, MA, Mark Wilcox, MD, Microbiology, Leeds Teaching Hospitals and University of Leeds, Leeds, United Kingdom, Sailaja Puttagunta, MD, Durata Therapeutics, Branford, CT and George Talbot, MD, Talbot Advisors LLC, Anna Maria, FL

Poster #: 1338

Title: An Integrated Analysis of the Efficacy of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (abSSSI) from the DISCOVER Program

Authors: Mark Wilcox, MD, Microbiology, Leeds Teaching Hospitals and University of Leeds, Leeds, United Kingdom, Helen Boucher, MD, FIDSA, Tufts New Engl Med Ctr, Boston, MA, George Talbot, MD, Talbot Advisors LLC, Anna Maria, FL, Anita Das, PhD, InClin, San Francisco, CA, Sailaja Puttagunta, MD, Durata Therapeutics, Branford, CT and Michael Dunne, MD, Durata Therapeutics, Inc., Branford, CT

Poster #: 1339

Title: Concordance of Clinical Response at 48-72 hours after Initiation of Therapy and End of Treatment (EOT) in Patients with Acute Bacterial Skin and Skin Structure Infection (abSSSI) in the DISCOVER Studies

Michael Dunne, MD, Durata Therapeutics, Inc., Branford, CT, Sailaja Puttagunta, MD, Durata Therapeutics, Branford, CT, Mark Wilcox, MD, Microbiology, Leeds Teaching Hospitals and University of Leeds, Leeds, United Kingdom, George Talbot, MD, Talbot Advisors LLC, Anna Maria, FL and Helen Boucher, MD, FIDSA, Tufts New Engl Med Ctr, Boston, MA

If you liked this article you might like

Why Durata Therapeutics (DRTX) Stock Hit a One-Year High Today

5 Stocks Moving on Unusual Volume

Emerging 'Superbugs' -- and Why Investors Should Care

2014 FDA Drug Approval Decision Calendar

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan